$MDCX News

Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome

Medicus Pharma Receives $22M In Non-Dilutive Financing

Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate

EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

Medicus Pharma reports strong Phase 2 dose response in skin cancer study

Medicus Pharma highlights positive dose-response in updated skin cancer trial results

Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response

EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study

Medicus Pharma Highlights Results From Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis; Says Data Reveal 'a clear and consistent dose-response relationship across endpoints'

Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome

Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill

Medicus Pharma advances Skinject in rare disease – ICYMI

Medicus Pharma files Orphan Drug application for SkinJect in rare skin Cancer indication

Medicus Pharma seeks orphan drug status for SkinJect in rare skin cancer disorder

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Files Orphan Drug Designation To FDA For SkinJect To Treat Basal Cell Carcinoma In Participants With Gorlin Syndrome

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting